In our fast-paced world, a great deal can happen in 12 months. Reflecting on this past year and my service as ACR president, I find this has certainly been the case.
Explore this issueOctober 2018
Also by this Author
For the foreseeable future, it appears the factors that influence our ability to effectively care for our patients with rheumatic and musculoskeletal disease will have less to do with scientific advances and the development of new therapies than with the policies and economics of healthcare. Thus, the ACR advocacy team has certainly had a busy year; legislative and policy issues have required major and ongoing attention.
Challenging Policy Landscape
I am continually impressed by the nimbleness and effectiveness of the public affairs and media relations staff and the volunteers of the ACR Government Affairs Committee who rapidly deal with complex issues as they arise. Unfortunately, the satisfaction that came earlier this year from achieving success on several legislative initiatives the ACR strongly supported (e.g., repealing the annual caps on physical therapy, repealing IPAB and preventing quality program payment adjustments from being applied to Part B drug reimbursement) was short-lived. In their place, new—and potentially much more pressing—issues have arisen.